glp-1 alternative for weight loss As an to injections, a pill has now been approved management GLP-1 Drug Savings: A Complete

The demand for tirzepatide has outpaced supply since its launch, and the search for effective alternatives has become one of the most common questions in weight management and metabolic health research

The starting dose period occupies the first 4 to 8 weeks

Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026

Rates of ischemic optic neuropathy were similar between groups at each time point, with no statistically significant differences observed